Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
06. Februar 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a...
Icosavax Reports Second Quarter 2023 Financial Results and Provides Corporate Update
14. August 2023 16:05 ET
|
Icosavax, Inc.
- Positive topline interim Phase 1 results for bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults - - Positive twelve-month immunogenicity data and initial proof-of-concept...
Icosavax Provides Corporate Update and Anticipated Milestones for 2023
06. Januar 2023 08:00 ET
|
Icosavax, Inc.
- Recently reported positive six-month immunogenicity data for IVX-121 against RSV; first clinical evidence of potential differentiation on durability with company’s VLP platform - - Phase 1 study of...
Icosavax Reports Second Quarter 2022 Financial Results and Provides Corporate Update
15. August 2022 16:05 ET
|
Icosavax, Inc.
– Announced positive topline interim Phase 1/1b results for VLP vaccine candidate IVX-121 against respiratory syncytial virus (RSV) - – Icosavax plans to file an IND and initiate a Phase 1 trial...
Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases
21. Juni 2022 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that two-year persistence data from its phase 2 clinical study evaluating the safety and...
Icosavax Announces Topline Interim Phase 1/2 Results for IVX-411 Against SARS-CoV-2
25. März 2022 08:00 ET
|
Icosavax, Inc.
- Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than expected and inconsistent with known data on company’s platform and VLP technology;...
Ressources Robex Inc. : nomination d’un fournisseur de service pour la tenue de marché
28. Januar 2022 13:00 ET
|
Ressources Robex Inc.
QUÉBEC, 28 janv. 2022 (GLOBE NEWSWIRE) -- Ressources Robex Inc. (« Robex », la « Société », le « Groupe » ou la « Compagnie ») (TSXV : RBX) À la suite de l’impact de la faible liquidité pesant...
Robex Resources Inc.: Retains Market-Making Services
28. Januar 2022 13:00 ET
|
Robex Resources Inc.
QUEBEC CITY, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Robex Resources Inc. (“Robex”, the “Corporation”, the “Group” or the “Company”) (TSXV: RBX) Following the significant change in the share...
Icosavax Appoints Dr. John Shiver to Board of Directors
05. Januar 2022 08:00 ET
|
Icosavax, Inc.
SEATTLE, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax to Participate in Upcoming Investor Conferences
11. November 2021 16:22 ET
|
Icosavax, Inc.
SEATTLE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...